<DOC>
	<DOCNO>NCT01284348</DOCNO>
	<brief_summary>The purpose study determine effective safe dose ACE-011 treatment chemotherapy induce anemia ( CIA ) patient metastatic non-small cell lung cancer treat first-line platinum base chemotherapy .</brief_summary>
	<brief_title>Study ACE-011 Determine Safe Effective Dose ACE-011 Treatment Chemotherapy Induced Anemia Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Part 1 : Metastatic non-small small cell lung cancer , metastatic bladder , head neck , cervical cancer : Modified expand eligible tumor type include advanced metastatic solid tumor treat first-line platinum-based chemotherapy , exclude solid tumor treat curative intent , Part 1 study . Part 2 metastatic non small cell lung cancer ; Modified confirm metastatic NSCLC subject eligible Part 2 study</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>1 . Men woman &gt; 18 year age 2 . Part 1 : Histologically confirm ( cytology biopsy ) solid tumor malignancy , exclude solid tumor treat curative intent . Part 2 : Histologically confirm nonsmall cell lung cancer 3 . Documented metastatic disease 4 . Measurable nonmeasurable disease evaluable Response Evaluation Criteria Solid Tumors ( RECIST ) 5 . All following laboratory value : Hemoglobin ≥ 6.5 &lt; 11.0 g/dL ( ≥ 65 &lt; 110 g/L ) , due chemotherapyinduced anemia Absolute neutrophil count ≥ 500/mm3 Platelet count ≥ 75,000/mm3 ( &gt; 72 hour since prior platelet transfusion Adequate renal function creatinine clearance ≥ 40mL/min ≥ 50 mL/min cisplatin concomitantly administer urine protein / creatinine ratio ≤ 1.0 ; ≤ 2.0 bevacizumab ( Avastin® ) concomitantly administer Hepatic function ( bilirubin &lt; 1.5 x ULN ; AST ALT &lt; 3.0 x ULN ≤ 5.0 ULN subject liver metastasis ) 6 . Subjects must receive : least one cycle 4 cycle ( q3w schedule ) platinumbased chemotherapy randomize prior receive Cycle 5 OR least one cycle 3 month ( depend upon regimen ) platinumbased chemotherapy 7 . &gt; 28 day since previous treatment ESA 8 . &gt; 14 day since last red blood cell transfusion 9 . Eastern Oncology Cooperative Group ( ECOG ) Performance status 02 10 . For female childbearing potential , highly effective method birth control least 28 day start study , participation least 112 day follow last dose ACE011 11 . Males must use latex condom nonlatex condom make ( animal ) membrane sexual contact female childbearing potential 12 . Life expectancy &gt; 3 month 13 . Willing adhere study visit schedule 14 . Understand voluntarily sign inform consent Part 2 , history prior regimen ( ) platinumbased chemotherapy metastatic NSCLC and/or history adjuvant platinumbased chemotherapy last dose receive less six month prior start current firstline platinumbased chemotherapy metastatic NSCLC . 1 . National Cancer Institute Common Terminology Adverse Events Grade &gt; 3 toxicity 2 . Prior radiation &gt; 20 % whole skeleton 3 . Prior regimen ( ) platinum base chemotherapy metastatic disease and/or history adjuvant platinumbased chemotherapy last dose receive less six month prior start current firstline platinumbased chemotherapy metastatic disease 4 . Central nervous system metastases 5 . Clinically significant pulmonary , endocrine , neurologic , gastrointestinal , hepatic , genitourinary disease unrelated underlying malignancy 6 . Classification 3 high heart failure ( classified New York Heart Association ) 7 . History thrombosis , deep vein thrombosis , pulmonary embolus , embolic stroke , stable anticoagulant and/or one event occur past 6 month 8 . Diagnosis myeloid malignancy know history myelodysplasia 9 . Recent history ( within 14 day Day 1 ) IV/oral antibiotic due post septic episode 10 . Uncontrolled hypertension . Controlled hypertension consider clinically stable , systolic blood pressure ( SBP ) must &lt; 150 mmHg diastolic blood pressure ( DBP ) must &lt; 100 mmHg . 11 . Known human immunodeficiency virus ( HIV ) 12 . Known active hepatitis B C antibody 13 . Iron deficiency 14 . History anemia result inherit hemoglobinopathy 15 . History anemia due autoimmune hereditary hemolysis gastrointestinal bleeding 16 . Received treatment another investigational drug device within 28 day prior Day 1 , half life previous product know , within 5 time half life prior dose , whichever may longer . 17 . Any prior use Sotatercept ( ACE011 ) . 18 . Pregnant lactating female females plan become pregnant 19 . History severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational product ( Refer Investigator 's Brochure information ) . 20 . Major surgery within 30 day prior Day 1 ( subject must completely recover previous surgery prior Day 1 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Chemotherapy induce anemia</keyword>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>